Phase III Trial of Irinotecan-Based Chemotherapy Plus Cetuximab with or without Bevacizumab as Second-Line Therapy for Patients with Metastatic Colorectal Cancer who have Progressed on Bevacizumab with either FOLFOX, OPTIMOX or XELOX (temporarily suspended on June 6)

This research study is for patients with colorectal cancer that has spread and has not responded to treatment including bevacizumab (Avastin).  The purpose of this study is to compare the effects of not adding bevacizumab, or of adding either a lower dose or a higher dose of bevacizumab to cetuximab plus an irinotecan-based treatment.